Real-World Outcomes after 36-Month Treatment with Ranibizumab 0.5 mg in Patients with Visual Impairment due to Diabetic Macular Edema (BOREAL-DME).
Ophthalmic Res
; 64(4): 577-586, 2021.
Article
en En
| MEDLINE
| ID: mdl-32932257
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Edema Macular
/
Diabetes Mellitus
/
Retinopatía Diabética
Tipo de estudio:
Clinical_trials
/
Diagnostic_studies
/
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Adult
/
Humans
/
Male
Idioma:
En
Año:
2021
Tipo del documento:
Article